Navigation Links
Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement

MADISON, Wis., July 1 /PRNewswire/ -- Cellular Dynamics International (CDI) and Roche announced today a significant expansion of their existing agreement to test drug development candidates for their potential to cause cardiotoxicity, or damage to heart tissue. The two-year collaboration aims to enhance drug safety testing in order to bring promising therapies to patients faster.

Under this agreement, CDI will supply purified cardiomyocytes, created from induced pluripotent stem cells (iPSCs), to Roche, and the two companies will collaborate to perform various cell characterization, toxicological, and electrophysiological response experiments. The agreement also includes an ongoing cardiomyocyte supply contract post collaboration.

Embarked upon originally in March 2008 as a validation of CDI's human pluripotent stem cell technology, the expanded agreement is a testament to the success of the first phase. This next phase moves the companies toward assessing iPSC-derived cardiomyocytes as a cardiovascular safety pharmacology as well as toxicology tool.

iPSCs are adult tissue cells that have been reprogrammed to a pluripotent, embryonic-like state. Like embryonic stem cells, iPSCs have the ability to differentiate into any cell type in the body. However, because they are created from adult skin cells, not embryos, they enable patient-specific stem cells, an important factor in moving the technology toward personalized medicine.

The goal of the agreement's next phase is to detect drug-induced changes in cardiomyocyte activity across a spectrum of compounds. While it is already standard practice to perform in vitro testing of drug candidates on cardiomyocytes, the cell models currently used have a limited utility to reliably predict conduction-related effects and/or overt cardiotoxicity. CDI's iPSC-derived cardiomyocytes could overcome these limitations by providing a human-based, genetically diverse, virtually unlimited cell supply. Together these attributes provide a platform expected to streamline drug development and more accurately predict human physiological responses.

"We are thrilled with the expansion of our Roche human cardiomyocyte program," said Robert Palay, CDI Chief Executive Officer. "We view this as the next logical step in providing Roche with high quality iPSC-derived human cardiomyocytes in sufficient volumes for their drug toxicity and development needs, thereby helping to bring safe and effective medicines to patients faster."

Commenting on the expanded agreement, Chris Kendrick-Parker, CDI Chief Commercial Officer, said, "CDI well understands the limitations associated with current in vitro testing models that do not appropriately reflect the target cell population and physiology. Our iPSC technology overcomes these obstacles and offers the promise of generating differentiated cell types, even personalized cell types, from virtually any genetic background. We believe iPSC technology will play a pivotal role as drug discovery and development practices continue to evolve toward personalized therapeutics, and we are excited to be working with a world-class organization such as Roche in this endeavour."

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPS technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cell research at the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based venture capital fund. CDI's facilities are located in Madison, Wisconsin. See


    Cellular Dynamics International, Inc.
    Joleen Rau
    Senior Director, Marketing & Communications
    (608) 310-5142

    Tony Russo

    Robert E. Flamm, Ph.D.

SOURCE Cellular Dynamics International (CDI)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
2. MIT, BU engineer cellular circuits that count events
3. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
4. Orange and Medic4all Launched the Worlds First Cellular Tele-Health Service
5. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
6. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
7. Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology
8. New insights into cellular reprogramming revealed by genomic analysis
9. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
10. Having Penetrated Israels Domestic Telephony Market, 012 Smile.Communications Prepares for Its Next Goal: Entering Israels Cellular Market
11. Cellular construction methods emulated
Post Your Comments:
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... LEXINGTON, Massachusetts , November 24, 2015 ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ... Poulton , Chief Financial Officer, will participate in the Piper Jaffray ... City , NY on Tuesday, December 1, 2015, at 8:30 ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the environment are paramount. Insertion points for in-line sensors can represent a weak ... the InTrac 781/784 series of retractable sensor housings , which are designed ...
(Date:11/24/2015)... 24, 2015 HemoShear Therapeutics, LLC, a ... for metabolic disorders, announced today the appointment of ... of Directors (BOD). Mr. Watkins is the former ... Sciences (HGS), and also served as the chairman ... Powers , Chairman and CEO of HemoShear Therapeutics. ...
Breaking Biology Technology:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
Breaking Biology News(10 mins):